Rintodestrant (G1T48) is an orally bioavailable selective estrogen receptor degrader (SERD) discovered in Greg Thatcher's lab at UIC and developed by G1 Therapeutics for the treatment of estrogen receptor-positive (ER+) breast cancer.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.